Jacek Jassem

Q: What Schools Are Affiliated With Jacek Jassem

Jacek Jassem is affiliated with the following schools: Lund University, National Taiwan University, University of Turin, Karolinska Institute, Heidelberg University, Medical University of Vienna, Poznań University of Medical Sciences, Medical University of Łódź, University of Sussex, Medical University of Lublin, University of Alberta, Charles University, Medical University of Gdańsk

Jacek Jassem's AcademicInfluence.com Rankings

Jacek Jassem

Medical

#2131

World Rank

#2531

Historical Rank

Oncology

#119

World Rank

#123

Historical Rank

medical Degrees

Jacek Jassem

Philosophy

#6252

World Rank

#9254

Historical Rank

Logic

#3434

World Rank

#4589

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Jacek Jassem Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jacek Jassem's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. (2006) (4805)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (2018) (2744)
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. (2013) (1947)
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. (2004) (1787)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019) (1742)
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. (2010) (1675)
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. (2006) (1410)
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) (2005) (1389)
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial (2007) (836)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. (2015) (688)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer (2009) (588)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. (2020) (587)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo (2015) (412)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. (2007) (383)
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. (2014) (363)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. (2006) (328)
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. (2016) (322)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. (2008) (310)
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. (2001) (310)
Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. (2013) (289)
Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. (2008) (276)
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. (2017) (258)
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. (2018) (251)
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. (2000) (243)
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. (2007) (229)
Staging and prognostic factors in small cell lung cancer: a consensus report (1989) (227)
Radiotherapy-induced thyroid disorders. (2004) (224)
Third consensus on medical treatment of metastatic breast cancer. (2007) (219)
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. (2007) (218)
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. (2017) (218)
BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer (2007) (213)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. (2008) (211)
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. (2008) (205)
Cardiovascular effects of systemic cancer treatment. (2011) (201)
Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer (2011) (172)
Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. (2004) (166)
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. (2005) (164)
Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) (2007) (158)
An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer (2009) (157)
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. (2009) (155)
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. (2014) (153)
FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies (2014) (144)
Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer (2012) (144)
Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). (2010) (127)
Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. (2010) (127)
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. (2011) (126)
IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC (2019) (121)
Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. (2014) (120)
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing (2013) (119)
Delays in diagnosis and treatment of breast cancer: a multinational analysis. (2014) (119)
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. (2016) (115)
Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid (2012) (114)
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer (2012) (109)
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. (2010) (109)
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. (2014) (109)
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. (2007) (102)
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers (2016) (102)
Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung (2008) (101)
Cardiovascular effects of breast cancer radiotherapy. (2007) (100)
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. (2005) (98)
PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer (2017) (97)
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. (2020) (96)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. (2012) (95)
A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. (2001) (92)
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain (2012) (91)
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. (2008) (89)
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis (2016) (89)
Complications of breast-cancer radiotherapy. (2006) (85)
A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. (2004) (84)
Second consensus on medical treatment of metastatic breast cancer. (2007) (83)
Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). (2017) (82)
Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer (2011) (80)
First mature analysis of the Intergroup Exemestane Study. (2006) (78)
Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. (2010) (77)
Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients (1993) (77)
Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases (2018) (77)
Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy. (2000) (75)
A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC) (2005) (73)
Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma (2005) (71)
Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. (2000) (69)
The role of radiotherapy in lung cancer: where is the evidence? (2007) (69)
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes (2010) (69)
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1‐Positive Lung Cancer (2016) (68)
Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project (2017) (66)
Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). (2013) (66)
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. (2008) (65)
MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). (2004) (63)
Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity. (2004) (62)
DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. (2014) (61)
Tobacco smoking after diagnosis of cancer: clinical aspects. (2019) (61)
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. (2004) (57)
Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies (2008) (57)
TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis (1997) (57)
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. (2010) (57)
Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). (2016) (56)
MicroRNA in lung cancer diagnostics and treatment. (2011) (56)
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. (2015) (55)
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. (2006) (55)
Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner (2014) (54)
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. (1998) (53)
Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer (2016) (53)
Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer (2008) (52)
Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences. (2003) (52)
Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung Cancer (2010) (52)
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. (2012) (51)
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. (2019) (51)
Oral vinorelbine: feasibility and safety profile. (2001) (50)
Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients. (2006) (50)
E-Cigarettes and Cancer Patients (2014) (50)
Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. (2015) (49)
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. (2018) (49)
1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (49)
Late complications after postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases with application of linear-quadratic model. (1998) (48)
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. (2018) (47)
Diagnosis and management of neck metastases from an unknown primary. (2005) (47)
Relationship between acute and late normal tissue injury after postoperative radiotherapy in endometrial cancer. (2002) (46)
Tobacco control in Poland-successes and challenges. (2014) (44)
The European Cancer Patient’s Bill of Rights, update and implementation 2016 (2016) (44)
Serum lipid profile discriminates patients with early lung cancer from healthy controls. (2017) (44)
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. (2015) (43)
Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. (1997) (43)
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer (2017) (43)
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. (2012) (43)
Chemotherapy of advanced non-small cell lung cancer. (1999) (42)
Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. (2003) (41)
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. (2012) (41)
A catalyst for change: the European cancer Patient's Bill of Rights. (2014) (41)
Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen (2007) (40)
Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer. (2001) (40)
The EORTC Breast Cancer Group: 40 years of research contributing to improve breast cancer management. (2002) (39)
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen (2009) (39)
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North‐Eastern Poland (2000) (38)
Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. (2016) (38)
The effects of tamoxifen on the female genital tract. (2004) (37)
Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. (1999) (37)
Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer. (2021) (37)
Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx (2005) (36)
Prognostic value of microRNA expression in operable non-small cell lung cancer patients (2014) (36)
Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform (2018) (34)
Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients (2015) (34)
A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life. (2002) (34)
Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. (2002) (33)
Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial. (2014) (33)
MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. (2018) (32)
The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study (2014) (32)
Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes. (2013) (32)
The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. (2009) (32)
P53 and K‐ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma (2004) (31)
Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy (2006) (31)
Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. (2018) (31)
Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer (2015) (31)
Caring for relatives with lung cancer in Europe: an evaluation of caregivers’ experience (2015) (31)
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. (2015) (31)
Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes (2007) (30)
Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC). (2006) (30)
Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma (2006) (30)
Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. (2018) (30)
Combined treatment with cytoprotective agents and radiotherapy. (2010) (29)
Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
The influence of blood transfusion on survival in operated non-small cell lung cancer patients. (2003) (28)
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report. (2005) (28)
Branchiogenic carcinoma--conceptual or true clinico-pathological entity? (2005) (28)
[The new TNM classification in lung cancer]. (2010) (28)
Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC) (2005) (28)
Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff (2014) (28)
A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. (1997) (28)
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. (2009) (27)
Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature (2011) (27)
High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts) (2007) (26)
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (26)
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort (2019) (26)
1303PDNivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status (2017) (26)
Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients. (2013) (26)
A randomized phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (25)
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. (2011) (25)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. (2012) (25)
International multidisciplinary expert panel consensus on breast reconstruction and radiotherapy (2019) (25)
Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation. (2004) (25)
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies (2011) (25)
EPR/alanine dosimetry in LDR brachytherapy--a feasibility study. (2006) (25)
A Phase III, Randomized, Double‐Blind, Placebo‐Controlled Trial of Pegfilgrastim in Patients Receiving First‐Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti‐VEGF Evaluation Study (PAVES) (2017) (24)
Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. (1993) (24)
Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. (2012) (24)
20 Gy in five fractions versus 8 Gy in one fraction in palliative radiotherapy of bone metastases. A multicenter randomized study (2003) (23)
Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits (2020) (23)
The Hamburg statement: the partnership driving the European agenda on breast cancer. (2004) (23)
Intraocular malignant teratoid medulloepithelioma in an adult: clinicopathological case report and review of the literature. (2006) (23)
Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer. (2012) (23)
Types and localisation of p53 gene mutations: a report on 332 non-small cell lung cancer patients. (2001) (23)
Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer. (2009) (23)
Loss of heterozygosity at chromosomes 3p and 17p in primary non-small cell lung cancer. (2004) (23)
Gene copy numbers of HER family in breast cancer (2007) (23)
Sertoli cell tumor in androgen insensitivity syndrome--a case report. (1999) (22)
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer (2017) (22)
Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01). (2014) (22)
Serum mass profile signature as a biomarker of early lung cancer. (2016) (22)
Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. (2018) (22)
Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study. (2017) (22)
Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer (2012) (22)
Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). (2009) (22)
Rectal doses in intracavitary brachytherapy of gynecological malignancies: comparison of two dosimetric methods. (2001) (22)
Systemic therapy for cervical carcinoma - current status. (2018) (21)
Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients (2013) (21)
Pattern of care in locally advanced breast cancer: focus on local therapy. (2011) (21)
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). (2006) (21)
Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. (2012) (21)
Blue-dye intraoperative sentinel lymph node mapping in early non-small cell lung cancer. (2006) (21)
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer (2018) (21)
Cardiac involvement at presentation of non-small-cell lung cancer. (2008) (20)
Sarcoma of the uterus (1956) (20)
LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. (2012) (20)
Changes in lateral dimensions of irradiated volume and their impact on the accuracy of dose delivery during radiotherapy for head and neck cancer. (2006) (19)
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. (2018) (19)
Miliary brain metastases in a patient with ROS1-rearranged lung adenocarcinoma: a case report. (2014) (19)
Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. (1998) (19)
Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). (2015) (19)
Hypofractionated radiotherapy for early breast cancer: Review of phase III studies. (2012) (18)
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS) (2015) (18)
Long-Term Follow-Up of the Intergroup Exemestane Study. (2017) (18)
Partial breast irradiation techniques in early breast cancer. (2011) (18)
Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial (2009) (18)
A Three‐Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines (2013) (18)
Factors determining acute normal tissue reactions during postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases. (2003) (18)
Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies. (2009) (17)
Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. (2001) (17)
Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer (2012) (17)
Chemotherapy in the primary treatment of cervical carcinoma. (2005) (17)
Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression (2005) (17)
Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). (2010) (17)
Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881 (1998) (17)
Cancer of the lung, pleura and mediastinum (2019) (16)
Multidisciplinary team care in advanced lung cancer (2020) (16)
Abstract P6-14-01: Effect of Denosumab Versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase (2010) (16)
A View from the past into our collective future: the oncofertility consortium vision statement (2021) (16)
Brussels Statement document. (2001) (16)
Combining systemic therapies with radiation in breast cancer. (2009) (16)
Brain Metastasis Prediction by Transcriptomic Profiling in Triple‐Negative Breast Cancer (2017) (15)
Primary cancer of the fallopian tube (1996) (15)
Autopsy findings in small cell lung cancer. (1996) (15)
A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC). (2013) (15)
Radiotherapy for non-small cell lung cancer. (2001) (15)
The European Code of Cancer Practice. (2021) (15)
Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer (2015) (15)
Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype. (2013) (15)
P3-16-07: Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: Results from the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study. (2011) (15)
MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC): FROM PROOF-OF-CONCEPT TO PHASE III TRIAL (MAGRIT) (2009) (15)
Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group. (1992) (14)
EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use? (2013) (14)
Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. (2012) (14)
The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe (2015) (14)
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours (2019) (14)
Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation. (2017) (14)
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments. (2012) (14)
Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES). (2009) (14)
Second lower genital tract squamous cell carcinoma following cervical cancer. A clinical study of 46 patients. (2000) (14)
Epoetin beta therapy in patients with solid tumours. (2006) (14)
Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51. (2013) (14)
"Teachable Moment" Interventions in Lung Cancer: Why Action Matters. (2018) (13)
Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. (2014) (13)
Phase II study of 4′-Epi-Doxorubicin in patients with untreated, extensive small Cell Lung Cancer (1990) (13)
Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). (2013) (13)
Gemcitabine and anthracyclines in breast cancer. (2003) (13)
Folate/homocysteine metabolism and lung cancer risk among smokers (2019) (13)
Consensus on Medical Treatment of Metastatic Breast Cancer (2003) (13)
Transcriptomic landscape of blood platelets in healthy donors (2021) (13)
Absence of prognostic significance of p21WAF1/CIP1 protein expression in non-small cell lung cancer (2005) (13)
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis. (2019) (13)
O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma (2003) (12)
A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). (2011) (12)
Patient-related factors determining geometry of intracavitary applicators and pelvic dose distribution during cervical cancer brachytherapy. (1997) (12)
Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. (2004) (12)
Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. (2010) (12)
Consensus on medical treatment of non-small cell lung cancer. (2002) (12)
Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies. (2009) (12)
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts) (2008) (12)
Post-mastectomy radiation therapy after breast reconstruction: Indications, timing and results. (2017) (12)
Expression of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC)--a preliminary report. (2001) (12)
Primary leiomyosarcoma of the mesentery in two sisters: clinical and molecular characteristics. (2013) (12)
Public perception of cancer care in Poland and Austria. (2015) (11)
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†. (2015) (11)
Treatment of recurrent vulvar Paget disease with imiquimod cream: a case report and review of the literature (2010) (11)
Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations (2015) (11)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 ( TLR 9 agonist ) as first-line treatment of advanced non-small-cell lung cancer (2011) (11)
Abstract P5-19-01: Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1 (2015) (11)
The Relationship of Cetuximab-Induced Rash and Survival in Patients with Head and Neck Cancer Treated with Radiotherapy and Cetuximab (2005) (11)
The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors. (2003) (11)
Chemotherapy in locally advanced head and neck cancer: a critical reappraisal. (1995) (11)
Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: a randomised phase III study (EORTC 10974/22002, LAMANOMA)--why did this study fail? (2005) (10)
Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. (2003) (10)
A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results (2007) (10)
European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission. (2022) (10)
Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer. (1992) (10)
The future of breast cancer research in danger. (2002) (10)
Palliative irradiation of bone metastases: patterns of care with focus on single fraction treatment (2004) (9)
Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM). (2015) (9)
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up (2022) (9)
Chronological Trends in Progression-free, Overall and Post-progression Survival in First-line Therapy for Advanced Non-small-cell Lung Cancer. (2019) (9)
Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab (2017) (9)
Intergroup Exemestane Study mature analysis: overall survival data. (2008) (9)
CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology. (2012) (9)
Klinefelter syndrome and neoplasia presentation of three new cases. (1996) (9)
13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer. (2012) (9)
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression (2021) (9)
Lung Cancer in Poland. (2020) (9)
imPlatelet classifier: image‐converted RNA biomarker profiles enable blood‐based cancer diagnostics (2021) (9)
Time without symptoms and toxicity (TWIST) analysis of adjuvant radiation therapy for endometrial cancer. (2004) (9)
Clinical implications of molecular abnormalities in lung cancer. (1998) (9)
Randomized open-label phase III multicenter trial comparing TAXOL®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer (1999) (8)
Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents (2021) (8)
The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions (2012) (8)
Detection and localization of early- and late-stage cancers using platelet RNA. (2022) (8)
Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: A South-East European Oncology Group study (2004) (8)
Conservative treatment for carcinoma of the anus--a report of 35 patients. (2003) (8)
Salvage hemipelvis radiotherapy with fertility preservation in an adolescent with recurrent vulvar carcinoma. (2002) (8)
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study (2019) (8)
The role of pemetrexed combined with targeted agents for non-small cell lung cancer. (2010) (8)
Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer. (2016) (8)
PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD‐L1–Selected Chemotherapy‐Naive NSCLC Patients: Topic: Medical Oncology (2016) (8)
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients (2015) (8)
Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluorouracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase iii trial of the Central European Cooperative Oncology Group (CECOG) (2001) (8)
MAGE-A3 GENE EXPRESSION FREQUENCY AND DEMOGRAPHY DATA OF STAGE IB-IIIA NSCLC PATIENTS FROM ONGOING MAGRIT PHASE III TRIAL EVALUATING MAGE-A3 ANTIGEN SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT TREATMENT (2010) (8)
ALK alterations in salivary gland carcinomas (2020) (7)
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study (2022) (7)
Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer (2021) (7)
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel (2010) (7)
801 Oral chemotherapy and upper gastro-intestinal tolerance (UGT) improvement of nausea and vomiting in non-small-cell-lung-cancer (NSCLC) patients (pts) treated with oral navelbine (NVB) and standard antiemetic prophylaxis (2003) (7)
The feasibility study on continuous 7-day-a-week external beam irradiation in locally advanced cervical cancer: a report on acute toxicity. (2001) (7)
Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer (2006) (7)
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. (2017) (7)
O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC (2020) (7)
Systemic therapy for endometrial stromal sarcomas: current treatment options. (2016) (7)
Prognostic Relevance of Altered pRb and p53 Protein Expression in Surgically Treated Non-Small Cell Lung Cancer Patients (2004) (7)
Combined modality treatment with chemotherapy and radiation in locally advanced non-small cell lung cancer. (2001) (7)
Combined chemotherapy and radiotherapy in inoperable non-small cell lung cancer. (2002) (7)
Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report (2021) (7)
A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results. (2012) (7)
Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis. (2010) (7)
Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments (2021) (7)
The role of hormonal factors and endocrine therapy in ovarian cancer (2013) (7)
IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). (2020) (7)
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis (2016) (7)
Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT) (2012) (6)
Influence of brachytherapy applicators geometry on dose distribution in cervical cancer (1997) (6)
Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group. (1992) (6)
FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC (2021) (6)
Molecular Profiles of Brain Metastases: A Focus on Heterogeneity (2021) (6)
Feasibility and safety of Navelbine oral (NVBpo) with an intrapatient dose escalation versus Navelbine intravenous (NVBiv) in advanced/metastatic non small cell lung cancer (NSCLC) (2000) (6)
[Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer]. (2005) (6)
Duration of Mucositis and Dysphagia following Radiotherapy (+ Cetuximab) for Locoregionally Advanced Head and Neck Cancer (2007) (6)
2101 ORAL Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting (2007) (6)
Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer? (1998) (6)
Evaluation of trastuzumab (Herceptin®), docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer (2007) (6)
166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study (2022) (6)
Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. (2007) (6)
Prognostic value of broad-spectrum keratin clones AE1/AE3 and CAM5.2 in small cell lung cancer patients undergoing pulmonary resection. (2019) (6)
Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study (2008) (5)
Pharmacogenomic research and serum DNA analysis in the treatment of non-small cell lung cancer (2001) (5)
Sarcoma of the uterus. A clinical study of 42 patients. (1996) (5)
Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial. (2018) (5)
Abstract OT1-1-16: LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment* (2012) (5)
Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review) (2021) (5)
Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients (2015) (5)
A stroma-related gene signature predicts resistance to epirubicin-containing neoadjuvant chemotherapy in breast cancer (2008) (5)
Predictive Biomarkers and Personalized Medicine Quantitative Measurements of Tumoral p 95 HER 2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab : Independent Validation of the p 95 HER 2 Clinical Cutoff (2014) (5)
Phase II study of 4'-epi-doxorubicin in patients with untreated, extensive small cell lung cancer. South-East European Oncology Group (SEEOG). (1990) (5)
Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). (2010) (5)
A prospective, randomized study to compare the value of two fractionation schedules of palliative radiotherapy (RT) for inoperable non-small cell lung cancer (NSCLC) (2001) (5)
Correction of Anemia with Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), in Oncology Patients Receiving Chemotherapy. (2007) (5)
Comparison of two techniques of interstitial pulsed dose rate boost brachytherapy in conservative treatment of breast cancer (2009) (5)
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC). (2013) (5)
B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study (2007) (5)
Chemotherapy of Metastatic Breast Cancer: Is more better? (2003) (5)
Expression profile of 29 genes by real-time quantitative PCR (RT-QPCR) in early-stage (I-IIIA) squamous cell carcinoma of the lung (SCCL) (2007) (4)
Relative dose intensity (RDI) relevance in adjuvant CMF chemotherapy of breast cancer (2006) (4)
[The role of radiotherapy in the management of esophageal cancer]. (2005) (4)
The role of surgery in limited-disease small cell lung cancer (SCLC); a retrospective comparative study. (2001) (4)
Cancer clinical trials in Central and Eastern Europe: historical review. (2002) (4)
Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens. (2019) (4)
Penile metastases from urogenital primaries. (2002) (4)
[Smoking and lung cancer]. (2009) (4)
6514 ORAL Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic (2007) (4)
Early presentation of results in clinical trials: an ethical dilemma for medicine and science. (1990) (4)
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. (2022) (4)
Analysis of IGF1R gene copy number by silver in situ hybridization (SISH) in non-small cell lung cancer (NSCLC). (2009) (4)
Combined chemotherapy and radiation (1997) (4)
Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study. (2013) (4)
[Treatment of advanced malignant melanoma with DTIC]. (1979) (4)
The occurrence of cerebellar hemangioblastoma in numerous first degree relatives with von Hippel-Lindau disease. (1999) (4)
Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer. (2011) (4)
Beneath the blood brain barrier: the challenge of diagnosis and management of central nervous system involvement in ALK-positive lung cancer. (2013) (4)
GENE EXPRESSION SIGNATURE IS A POTENTIAL PREDICTIVE FACTOR FOR EFFICACY OF MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC) (2008) (4)
Limitations of cancer care in Central and South-Eastern Europe: results of the international conference organized by the Central European Cooperative Oncology Group (CECOG) (2020) (4)
Insulin-like growth factor receptor 1 (IGF1R) protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer (NSCLC). (2009) (4)
Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901 (2004) (4)
Second lower genital tract squamous cell carcinoma following cervical cancer (2000) (4)
Breast cancer treatment patterns in Poland (2012) (4)
Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach. (2019) (4)
Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (2022) (4)
[Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma]. (2010) (4)
PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881) (1996) (4)
355TiPPhase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC (2015) (4)
Erratum: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer (2009) (4)
480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) (2016) (3)
AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab (2012) (3)
Effectiveness and costs of breast cancer therapy in Poland: a regional approach (2014) (3)
Predictive role of topoisomerase II α expression in anthracycline based breast cancer chemotherapy (2005) (3)
139. Parallel-opposed fields vs. four fields, and two- (2D) vs. three-dimensional (3D) radiotherapy planning in thin patients with gynecological malignancies (2003) (3)
Taxanes in the treatment of advanced breast cancer (2003) (3)
PDR brachytherapy: a report on one – year clinical experience at the Medical University of Gdańsk (2001) (3)
4′epidoxorubicin (Epi DX) in elderly or unfit patients (pts) with small cell lung cancer (SCLC): a phase II experience by the EORTC Lung Cancer Cooperative Group (1991) (3)
Parallel-opposed fields versus four fields, and two- versus three-dimensional radiotherapy planning in thin patients with gynecological malignancies. (2008) (3)
905 Documenting symptom palliation with chemotherapy using the LCSS-Meso: Results from the randomized trial of pemetrexed plus cisplatin vs cisplatin alone in patients with malignant pleural mesothelloma (2003) (3)
New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary (2022) (3)
Maintenance chemotherapy in advanced non-small-cell lung cancer. (2012) (3)
Diagnosis and treatment of breast cancer (2003) (3)
First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations (2022) (3)
Patient-related factors influencing time between first signs of breast cancer (BC) and appointment for medical visit (AMV): An international survey. (2012) (3)
P2-073: High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated patients with non-small cell lung cancer (NSCLC) (2007) (3)
D5-02: Increased BRCA1 mRNA: an independent prognostic variable in completely resected chemonaive non-small-cell lung cancer (NSCLC) patients (p) (2007) (3)
Validation of 5- and 3-gene expression signatures for predicting outcome in non-small cell lung cancer (NSCLC) patients (p) (2008) (3)
P5-19-01: Final Results of a Three-Arm Randomised Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines. (2011) (3)
Concomitant and alternating radiation therapy (RT) and chemotherapy (CT) for inoperable, M0, non-small cell lung cancers (NSCLC): a consensus report. (1994) (3)
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. (2022) (3)
Recommendations on the application of positron emission tomography in oncology (2015) (3)
Mediastinal malignant germ cell tumours: presentation of 15 cases and literature review (2003) (3)
In vivo dosimetry using electron paramagnetic resonance in L-alanine in gynecological low dose rate brachytherapy (2004) (3)
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC. (2020) (3)
Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies. (2014) (3)
Resolution of thymoma-related pure red cell aplasia after octreotide treatment (2007) (3)
Biological treatment of NSCLC. The need for conclusive studies. (1996) (3)
RAD51 and brain metastases (BM) in patients (pts) with HER2+ breast cancer. (2011) (3)
Cost analysis of chemotherapy in advanced non-small cell lung cancer (2001) (3)
Post-treatment surveillance in most common solid malignancies in adults (2014) (3)
Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone. (2019) (3)
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
Circulating immune complexes in patients with melanoma. (1981) (3)
2120 POSTER Retreatment with trastuzumab after relapse following adjuvant trastuzumab treatment (the RHEA trial): preliminary efficacy data (2007) (3)
Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer (2005) (3)
[Prognostic value of P53 protein in cells of non-small cell lung cancer]. (2000) (2)
An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number (2016) (2)
Polish and international recommendations on the treatment of breast cancer (2013) (2)
Dual HER2 Blockade (2017) (2)
Combined analysis of P53 Arg72Pro, GSTM1 and GSTT1 gene polymorphisms as predisposing factors for non-small cell lung cancer (NSCLC) development (2005) (2)
Impact of Tobacco Smoking on Outcomes of Radiotherapy: A Narrative Review (2022) (2)
[The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations]. (2014) (2)
Increased BRCA1 mRNA: An independent prognostic variable in completely resected chemo-naive non-small cell lung cancer (NSCLC) patients (p) (2007) (2)
143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC (2017) (2)
Postoperative chemotherapy in non-small cell lung cancer: still more questions than answers. (2006) (2)
[Platinum-based chemotherapy in renal transplant recipients with malignancies: a case report and review of literature]. (1998) (2)
Prognostic value of three microRNA expression profiles in early-stage squamous cell lung cancer (SqCLC). (2010) (2)
Chemoradiotherapy of non-small cell lung cancer. (2002) (2)
Clinical relevance of genetic alterations in lung cancer (1998) (2)
Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair‐matched immunohistochemical analysis aimed at intrinsic tumor phenotype (2014) (2)
Primary uterine leiomyosarcoma: outcome and prognostic factors in eighty consecutive patients. A rare cancer network study (2001) (2)
[Why the ban on smoking should be expanded in Poland?]. (2009) (2)
Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer (2016) (2)
Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer. (2020) (2)
International consensus on radiotherapy in metastatic non-small cell lung cancer (2021) (2)
Randomized clinical trials using new technologies in radiation oncology: ethical dilemma for medicine and science. (2012) (2)
[Late recurrence of malignant tumours 20 years after diagnosis and treatment]. (2007) (2)
Changes in lateral dimensions of irradiated volume and their impact on the accuracy of dose delivery during radiotherapy for head and neck cancer (2004) (2)
34. A multicenter randomized study of two regimens in paliative radiotherapy of bone metastases (2001) (2)
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence. (2022) (2)
[Analysis of prognostic factors for long term survival in patients with small cell lung cancer]. (1994) (2)
Paliatywna radioterapia chorych na raka płuca Palliative radiotherapy in lung cancer (2004) (2)
Expression of Bax and Bcl2 proteins in small cell lung cancer (SCLC) (2007) (2)
[Uterine carcinosarcoma]. (2012) (2)
Assessing the Burden of Caregiving for Patients with Lung Cancer in Europe (2013) (2)
[New imaging methods in diagnosis of lung cancer]. (1997) (2)
Breast cancer treatment expenditures in Poland (2013) (2)
Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis (2019) (2)
Abstract P1-03-03: High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay (2017) (2)
Post-operative radiotherapy in non-small-cell lung cancer: more questions than answers. (1996) (2)
806TiPSPARTAN - A RANDOMIZED DOUBLE-BLIND, COMPARATIVE STUDY OF ARN-509 PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS ADT ALONE IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (M0-CRPC). (2014) (2)
Clodronate in the management of bone metastases: a clinical study of 91 patients. (1999) (2)
Alectinib in crizotinib-resistant, ALK-positive NSCLC. (2016) (2)
ES20.01 Tobacco Cessation After Cancer Diagnosis: Declaration from IASLC (2019) (2)
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES (2017) (2)
Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases. (2012) (2)
Thymidylate synthase (TS) gene copy number in NSCLC. (2010) (2)
[Long-term survival of patients with small cell lung cancer]. (1989) (2)
Functional evaluation of postradiation lung injury (1996) (2)
Polish Recommendations on Enteral and Parenteral Nutrition in Oncology — part two: enteral nutrition (2013) (1)
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases (2022) (1)
Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer (2016) (1)
Current aspects of combined radiotherapy and chemotherapy (2000) (1)
O-0031EVALUATION OF KRAS, NRAS, AND BRAF MUTATIONS IN PRIME: PANITUMUMAB WITH FOLFOX4 AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) (2013) (1)
Abstract P6-11-07: Quantitative p95HER2 levels in primary breast cancers and in matched brain metastases (2013) (1)
P-750 The impact of primary pulmonary resection on local control and survival in limited disease (LD) small cell lung cancer (SCLC) patients (pts): A retrospective comparative study (2005) (1)
Post-treatment follow-up in common solid malignancies: expert panel recommendations (2022) (1)
HematideTM, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Assessed for Correction of Anemia in Oncology Patients Receiving Chemotherapy. (2006) (1)
Stroma related gene signature predicts sensitivity to epirubicin containing neoadjuvant chemotherapy. A microarray study of 102 patients included in EORTC 10994/BIG 00-01 trial (2006) (1)
Profound neutropenia related to consolidation durvalumab following concurrent radiochemotherapy in III stage non-small-cell lung cancer patient. (2021) (1)
Individual moulds for contact pulsed dose rate brachytherapy in head and neck cancer (2005) (1)
The algorithm assessing the value of new anticancer drugs — the proposal of the Polish Society of Clinical Oncology and Polish Oncological Society (2015) (1)
Letter to the editor. Reply. (2013) (1)
[Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer]. (1998) (1)
Abstract P5-02-02: Factors influencing time to seeking medical advice and start of treatment in breast cancer (BC) patients – an International survey (2012) (1)
5000 A 3-arm randomised phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines (2009) (1)
Abstract 5306: Overexpression of RAD51 promotes brain metastases from breast cancer (2012) (1)
MDM 2 Gene Amplification and Expression in Non − Small − Cell Lung Cancer Patients * (2006) (1)
Chemoradiotherapy of nonsmall cell lung cancer (2002) (1)
Role of chemotherapy in the multimodality approach of non-small cell lung cancer. (2003) (1)
Enteral nutrition in cancer patients (2014) (1)
FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (2016) (1)
Continuous 7-days-a-week external beam irradiation in locally advanced cervical cancer: final results of the Phase I/II study. (2012) (1)
Exacerbation of diabetes related to exemestane treatment (2008) (1)
Hepatocellular carcinoma - diagnosis and treatment (2009) (1)
Paradigms in chemoradiotherapy (2007) (1)
Abstract 3700: Prognostic value of the expression ofNKG2DandCD96in early stage non-small cell lung cancer (NSCLC) (2017) (1)
Postoperative therapy for uterine carcinoma. Overview of randomized trials (2013) (1)
36. A prospective, randomized study to compare the value of two fractionation schemes of palliative radiotherapy for inoperable non-small cell lung cancer (2001) (1)
3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM) (2015) (1)
[Autoantibodies in patients with malignant tumors]. (1979) (1)
Complementary and Alternative Therapies in Oncology (2022) (1)
Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer (1993) (1)
10 Brachytherapy applicators geometry influences the quality of pelvic dose distribution in cervical cancer patients (1994) (1)
[Use of metoclopramide and dexamethasone in preventing vomiting associated with antineoplastic chemotherapy]. (1987) (1)
Chemotherapy for advanced NSCLC: any light at the end of the tunnel? (2007) (1)
Patterns of failure in small cell lung cancer (SCLC) (1993) (1)
Assessment of the new postsurgical pathological staging classification in NSCLC (1999) (1)
73. Concurrent weekly cisplatin and radiotherapy in cervical cancer patients. A report on acute toxicity (2001) (1)
Independent validation of prognostic value of 22 micrornas (miRs) in stage I-II squamous cell lung cancer (SqCLC). (2012) (1)
The methods of tumor bed localization and boost dose delivery during conservative breast cancer treatment (2004) (1)
[Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group]. (2007) (1)
Recombinant human erythropoietin in treatment of the cancer patients with anemia: hopes and threats (2007) (1)
Prognostic value of microRNAs (miRNAs) profiling in early-stage squamous cell lung cancer (SqCLC). (2009) (1)
Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy. (2010) (1)
Targeted therapies in advanced non-small cell lung cancer: success or failure? (2011) (1)
The scope of complementary and alternative medicine in Poland (2021) (1)
Quantitative measurements of p95HER2 (p95) and total HER2 (H2T) protein expression in patients with trastuzumab-treated, metastatic breast cancer (MBC): Independent confirmation of clinical cutoffs. (2011) (1)
Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations (2021) (1)
MS24.03 The Importance of Physician Involvement in Tobacco Control (2018) (1)
Prognostic significance of aneuploidy in non-small cell lung cancer (NSCLC) patients (pts) (2004) (1)
Expression of thymidylate synthase (TYMS) and Insulin growth factor 1 (IGF1) in completely-resected NSCLC patients: associations with histological subtype and prognosis (2009) (1)
Head and neck epithelial neoplasms (2003) (1)
Prognostic Significance of Wnt1, Wnt2, E-Cadherin, and β-catenin Expression in Operable Non-small Cell Lung Cancer (2021) (1)
Abstract 5136: Discovery of novel functional germline variations in the vascular endothelial growth factor receptor 2 gene (KDR) and their effect on gene expression and microvessel density in lung cancer (2011) (1)
PD-030 P53 colon 72 polymorphism increases the risk of somatic P53 gene mutations in non-small cell lung cancer (NSCLC) (2005) (1)
A comparison between DASL and Affymetrix on probing the whole-transcriptome (2016) (1)
Highlights from the San Antonio Breast Cancer Symposium 2015 (2016) (1)
Abstract 3190: Genomic profiling of salivary gland tumors identifies novel and targetable alterations (2016) (1)
Consensus statement with focus on cancer pain management (2009) (1)
Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-ARM randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861) (1990) (1)
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses. (2022) (1)
A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer (2005) (1)
Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer (LAMANOMA, EORTC 10974/22002). Why this study failed? (2004) (1)
Ef ﬁ cacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study (2014) (1)
Health-related quality of life (HQOL) and early survival outcome of the randomized adjuvant dose-dense (dd) FEC75 versus FEC90 CECOG study. (2010) (1)
P-924 Clinical impact of pre-treatment haemoglobin (HGB) level, whiteblood cell (WBC) and platelet (PLT) counts: Updated multivariate survival analysis of 639 operable non-small cell lung cancer (NSCLC) patients (2005) (1)
Short versus long term treatment with CMF in posthemopausal patients with advanced breast cancer; an eortc breast cancer co-operative group phase III trial (10852) (1993) (1)
PARP inhibitors beyond BRCA-mutated cancers: precision medicine at the crossroads (2021) (1)
(CA)n microsatellite polymorphism of ERBB-1 in breast cancer. (2006) (1)
Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation. (2018) (1)
Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16–20 March 2004 (2004) (1)
Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC). (2009) (1)
Pharmacotherapy of pain in cancer patients– recommendations of the Polish Association for the Studyof Pain, Polish Society of Palliative Medicine, Polish Societyof Oncology, Polish Society of Family Medicine, and PolishSociety of Anaesthesiology and Intensive Therapy (2018) (1)
Pathway-level mutation analysis in primary high-grade serous ovarian cancer and matched brain metastases (2022) (1)
P2.01-66 Genomic Landscapes of DNA Copy Number Alterations in Primary Lung Cancers and Matched Brain Metastases (2019) (1)
Comparison of claudin-3 and claudin-4 expression in bilateral and unilateral breast cancer. (2020) (1)
Changing paradigms in breast cancer treatment (2020) (1)
Abstract 4589: Overexpression of RAD51 promotes brain metastases from breast cancer. (2013) (1)
[IgG, IgM and IgA levels and presence of antinuclear factors and antibodies to smooth muscles in patients with malignant melanoma]. (1979) (1)
Thoracic neoplasms (2022) (1)
The role of boost in hypofractionated irradiation after breast-conserving surgery (2015) (1)
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (1)
Paraganglioma of the neck. Case study of two patients treated with intensity modulated radiation therapy (IMRT) (2011) (1)
Alternating and sequential administration of docetaxel with fluorouracil, epirubicin and cyclophosphamide have similar safety profiles for metastatic breast cancer (2002) (1)
Bright and dark sides of evidence-based medicine. (2016) (1)
Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype. (2013) (1)
Spinal cord ependymoma: Retrospective analysis of treatment outcomes of 14 patients (2004) (1)
Exemestane: an alternative treatment option in early breast cancer. Foreward. (2008) (1)
Lung cancer in Europe: The way forward (2022) (1)
Lung cancer chemoprevention - focus on surrogate markers (2005) (1)
[Prevention of emesis accompanying antitumor chemotherapy]. (1994) (0)
[Immunotherapy of lung cancer]. (1982) (0)
P5-13-07: MET and Hepatocyte Growth Factor (HGF) Increased Gene Copy Number Is Associated to Trastuzumab Failure in HER2 Positive Metastatic Breast Cancer (MBC). (2011) (0)
Pulsed-dose-rate post-operative vaginal cuff brachytherapy for endometrial cancer : preliminary report (2015) (0)
Inhibition of leukocyte migration by soluble tumor extracts in human malignant melanoma. (1980) (0)
Prediction of brain relapse by gene expression analysis in HER2-positive metastatic breast cancer patients (2008) (0)
Combined chemotherapy and radiation in NSCLC (1999) (0)
180. The role of surgery in management of limited disease (LD) small cell lung cancer (SCLC), a retrospective comparative study (2003) (0)
[Alterations of locus P16INK4a/P14ARF in non-small cell lung cancer]. (2003) (0)
World Tobacco Quitting Day 2020 – the united voice of Polish experts on tobacco prevention and control (2020) (0)
Skin reactivity to dinitrochlorobenzene in cancer patients. (1980) (0)
ASCO International Development and Education Award - an opportunity for young Polish oncologists (2005) (0)
Pulsed dose rate peri-operative brachytherapy (PDR BT) as an interstitial boost in conservative treatment (BCT) of breast cancer. Preliminary results (2004) (0)
SP-0416 COMBINED MODALITIES INCLUDING CHEMORADIATION AND MOLECULAR TARGETING (2012) (0)
67. Radical radiotherapy of muscle-invading bladder cancer (BC): a retrospective analysis of 49 patients (2001) (0)
P2-100: Real time RT-PCR based 3-gene expression signature predicts survival in early-stage squamous cell lung cancer (SqCLC) (2007) (0)
Management of local relapse in breast cancer (2006) (0)
Abstract P3-12-09: The risk of brain metastases according to expression of selected immunohistochemical markers in primary breast cancers (2012) (0)
Castleman’s disease mimicking lymph node metastases in a young woman with laryngeal cancer (2016) (0)
Occurrence and clinical significance of hOGG1 Ser326Cys polymorphism in NSCLC patients from Northern Poland: P2-011 (2007) (0)
Chemoradiotherapy of anal cancer – a report of 12 cases (1997) (0)
Intermittent/alternated therapy with tamoxifen and medroxy-progesterone acetate prolongs time to resistance to tamoxifen without benefit for (progression free) survival in patients with advanced breast cancer. Results of an EORTC phase III study (trial 10863) (2004) (0)
Management of relapses after primary therapy for prostate cancer (2003) (0)
Beyond Anthracyclines and Taxanes – Epothilones for Metastatic Breast Cancer (2008) (0)
Should breast cancer patients progressing on trastuzumab treatment continue with the drug? A commentary to the article by T. Pienkowski entitled ŇTrastuzumab - the present and the future of breast cancer treatment" (2005) (0)
Individualization of chemotherapy regimens including 5-fluorouracil in patients with colorectal cancer and head and neck cancer: theoretical and practical aspects (2012) (0)
Abstract B45: Analysis of c‐Met gene copy number by dual‐color silver in situ hybridization (SISH) in non‐small cell lung cancer (NSCLC) (2009) (0)
MTP7-01: Combined modality therapy for NSCLC (2007) (0)
Prognostic value of microRNAs expression in stage I-IIIA lung adenocarcinoma (AC) (2013) (0)
D6-07: A seventy two gene signature and survival in completely-resected non-small-cell lung cancer (NSCLC) (2007) (0)
1713PPrognostic value of NK and T-lymphocyte markers in operable non-small cell lung cancer (NSCLC) (2017) (0)
Taxoids in the treatment of breast cancer: a Round Table Conference (2004) (0)
The role of taxoids in the treatment of breast cancer – recommendations based on the results of reliable clinical trials (2006) (0)
Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer. (1994) (0)
P-655 Co-expression of p21WAF1/CIP1, p53, pRb, mdm2 and cyclin D1in NSCLC cells (2005) (0)
Pneumonological workshop Under the auspices of “ Polish Pneumonology and Allergology ” (0)
Abstract P2-05-21: Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib (2017) (0)
[Radiation pneumonitis]. (1997) (0)
[Genetic susceptibility to lung cancer]. (2000) (0)
[Efficacy and feasibility evaluation in long term pamidronate treatment of bone metastases]. (2003) (0)
Systemic therapy of colorectal cancer - consensus based on the results of clinical trials (2007) (0)
Legal and methodological aspects of genetic diagnostic tests used to select cancer patients to molecularly targeted therapies (2013) (0)
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC). (2016) (0)
Platelet RNA Signature Enables Early and Accurate Detection of Ovarian Cancer: An Intercontinental, Biomarker Identification Study (2021) (0)
Factors determining locoregional control and late sequelae in patients with locally advanced breast cancer (LABC) managed with radiotherapy (RT) as the primary locoregional treatment (2001) (0)
Lung cancer: a preventable disease. (2019) (0)
High prevalence of BRCA1 mutations in breast + ovarian cancer patients at the region of Gdansk, Poland (2004) (0)
Abstract P2-10-31: Correlation of quantitative p95HER2 and total HER2 levels with clinical outcomes in a combined analysis of two cohorts of trastuzumab-treated metastatic breast cancer patients (2012) (0)
Palliative radiotherapy in lung cancer (2004) (0)
Bisphosphonates in prevention and control of skeletal-related events in cancer patients with bone metastases (2006) (0)
Abstract P3-13-03: Molecular factors associated with bone metastases in breast cancer patients (2012) (0)
MALT - type orbital lymphoma: a case report and the review of the literature (2007) (0)
Gene expression profiles in non-small cell lung cancers (NSCLCs) and in corresponding healthy lung tissues in smokers versus nonsmokers. (2010) (0)
Serum anti-p53 antiobodies in SCLC: the lack of clinical relevance (1999) (0)
407 Abnormalities of erbB oncogenes in locally advanced breast cancer (2003) (0)
Clinical relevance of therapeutic benefit in anti-cancer drugs assessment (2015) (0)
The need for a comprehensive and integrated approach to lung cancer policy in Europe. (2022) (0)
Consensus on methods of development of clinical practice guidelines in oncology under the auspices of Maria Sklodowska-Curie National Research Institute of Oncology and the Agency for Health Technology Assessment and Tariff System (2022) (0)
P-116 Characteristics of P53 gene mutations in Polish non small cell lung cancer (NSCLC) patients (2005) (0)
Original A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients (2005) (0)
Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases (2018) (0)
Journal Pre-proof Genomic profiling identifies putative pathogenic alterations in non-small cell lung cancer brain metastases (2022) (0)
Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations (2015) (0)
Radiotherapy in thoracic malignancies: the preface (2021) (0)
60. Factors detremining local control in patients (Pts) with locally advanced breast cancer (Labc) managed with radiotherapy (RT) as the primary locoregional treatment (2001) (0)
[Mutation of gene p53 in lung cancer]. (1996) (0)
Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer (2022) (0)
Immunohistochemical, FISH and Genomic Profiling Study of Salivary Gland Carcinomas Reveals a Novel MYO18A-ALK Gene Rearrangement (2018) (0)
P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients: Topic: IT (2016) (0)
PROGNOSTIC SIGNIFICANCE OF RELATIVE DOSE INTENSITY OF ADJUVANT CMF CHEMOTHERAPY IN BREAST CANCER PATIENTS (2003) (0)
6520 ORAL Multi-gene prediction of distant relapse-free survival in early NSCLC: microarray expression-profiling study (2007) (0)
Comparative genomic profiling identifies targetable brain metastasis drivers in non-small cell lung cancer (2022) (0)
Monoclonal antibodies in the treatment of solid tumours (2005) (0)
Dyspnea in paties with lung cancer (2002) (0)
The role of ultrasonography in addition to mammography in the detection of breast cancer (2004) (0)
Postoperative radiotherapy combined with 5-fluorouracil in patients with rectal cancer (2000) (0)
Independent validation of prognostic value of 22 microRNAs (miRs) in stage I-II lung adenocarcinoma (AC) (2012) (0)
48. Combined chemotherapy and radiation in locally advanced NSCLC (2001) (0)
[Broncho-alveolar carcinoma--clinical picture and treatment methods]. (1992) (0)
Abstract B31: Fibroblast growth factor receptor-1 (FGFR1) gene amplification is frequent in lung squamous cell carcinoma and high gene copy number indicates a better prognosis in early stage NSCLC. (2011) (0)
Erlotinib as adjuvant therapy in EGFR-mutant NSCLC. (2018) (0)
P53 gene mutations are associated with poor prognosis in adenocarcinoma of the lung (1999) (0)
Platelet RNA Sequencing Data Through the Lens of Machine Learning (2022) (0)
[Local toxicity of cytostatics]. (1988) (0)
P5-01-06: Gene Copy Number and Expression of TYMP and TYMS Are Predictive of Outcome in Breast Cancer Patients Treated with Capecitabine. (2011) (0)
588 Mutational pattern of p53 gene in two European non-small cell lung cancer (NSCLC) populations: Null type mutations confer a poor prognosis (1997) (0)
P2-077: Prediction of distant relapse risk in stage I-II NSCLC by gene expression profiling (2007) (0)
New guidelines for the treatment of early breast cancer. Recommendations of the 9th International Conference in St. Gallen (2006) (0)
The relevance of new postsurgical TNM classification in NSCLC (1999) (0)
55. How often should we obtain complete blood counts (CBC's) from patients receiving radical radiation therapy? (2001) (0)
Contralateral esophageal sparing technique in definitive radiotherapy for non-small cell lung cancer: dosimetric parameters and normal tissue complication probability modeling (2022) (0)
MicroRNA (MiRNA) expression profiles in early colon cancer (CC) and lung adenocarcinoma (AC). (2015) (0)
The role of biological rhythms in cancer chemotherapy (2000) (0)
Upregulation of BRCA1: an independent prognostic variable in completely resected chemonaive non-small-cell lung cancer (NSCLC) patients (p) (2007) (0)
Quantitative measurements of p95HER2 (p95) protein expression in tumors from patients with metastatic breast cancer (MBC) treated with trastuzumab: Independent confirmation of the p95 clinical cutoff. (2013) (0)
1609 Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170) (2015) (0)
Phase II study of Gemcitabine (G) and Cisplatin (P) in advanced NSCLC. Focus on quality of life (QoL) (1999) (0)
Factors determining acute normal tissue reactions of postoperative radiotherapy in endometrial cancer (2001) (0)
P-562 Evaluation of bexarotene (Targretine®) in combination with cisplatin and vinorelbine in chemotherapy-naïve patients with advanced stage IIIb/IV non-small cell lung cancer (NSCLC) (2005) (0)
Abstract 5148: Non-small cell lung cancer expression ofVEGF pathway genes and association with heritable genetic variants (2011) (0)
Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients. (2012) (0)
[Intratumor BCG immunotherapy of advanced malignant melanoma]. (1981) (0)
Strategy of local treatment in prostate cancer (2003) (0)
Immunohistochemical (IHC) prediction of lapatinib efficacy in HER2-positive advanced breast cancer patients. (2014) (0)
Protein expression (PE) and increased IGF1R gene copy number (GCN) in small cell lung cancer (SCLC). (2010) (0)
Methods of random treatment allocation in clinical trials (2005) (0)
Occurrence and clinical significance of hOGG 1 Ser 326 Cys polymorphism in NSCLC patients from Northern Poland (2015) (0)
[Cobalt radioisotope teletherapy of patients with metastases to the brain]. (1987) (0)
Preferences and treatment possibilities for patients with breast cancer in Poland - questionnaire analysis (2006) (0)
Comment on the article (2017) (0)
449 Assessment of quality of life (QoL) in contemporary phase III trials in advanced breast cancer (ABC): is it worthwhile? (2010) (0)
Some aspects of cell-mediated hypersensitivity in patients with melanoma. (1980) (0)
Abstract 921: Fibroblast growth factor receptor 1 (FGFR1) protein expression and gene copy number in small cell lung cancer (2014) (0)
International conference on 'Non Small Cell Lung Cancer: Standards and New Trends in Diagnosis and Therapy', October 5-7, 2001, medical academy of Bialystok, Bialystok, Poland. (2002) (0)
Recommendations on the systemic treatment of non-small cell lung cancer:a Round Table Conference (2005) (0)
MDM2 Gene Amplification and Expression in Non−Small−Cell Lung Cancer Patients* Amplifikacja i ekspresja genu MDM2 u chorych na niedrobnokomórkowego raka płuca (2006) (0)
Comparison of three techniques of whole breast irradiation (WBI) and boost delivery for early breast cancer after breast conserving surgery (2006) (0)
of Polish and international guidelines on hormonal therapy in localized prostate cancer (2017) (0)
Brain Metastases from Breast Cancer in Patients Receiving Trastuzumab (2016) (0)
Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer. (2011) (0)
Hereditary prostate cancer (2003) (0)
Assessment of health related quality of life (QOL) in phase III trials in advanced colorectal cancer (CRC): Frequency, time trends, and QOL improvement. (2016) (0)
Can an Integrative SNP Approach Substitute Standard Identification in Comprehensive Case/Control Analyses? (2018) (0)
9041 Gene expression profiles according to smoking status in early non-small cell lung cancer (NSCLC) (2009) (0)
Implantation of a cervical carcinoma in the episiotomy site. A case report and review of the literature (1996) (0)
The assessment of cardiovascular injury and early and late lung complications after irradiation for breast cancer (2001) (0)
Prognostic and predictive significance of HER2 in breast cancer (2003) (0)
Surgery followed by irradiation in glioblastoma multiforme. A report of 28 cases (1997) (0)
Prognostic value of NK and T-lymphocytes markers in operable non-small cell lung cancer (NSCLC). (2017) (0)
500 POSTER Real time RT-PCR 3-gene expression signature predicts survival in early-stage squamous cell lung cancer (2007) (0)
Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containig regimen (2008) (0)
Chemotherapy for advanced colorectal patients: daily practice results may not reflect the outcomes of prospective clinical trials (2016) (0)
HER2 in breast cancer - the focus on assessment methods (2003) (0)
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast. (2022) (0)
Indications for high dose chemothin malignant neoplasmserapy supported by autologous hematopoietic cell transplantation in malignant neoplasms (2007) (0)
Surgical approaches to early breast cancer in the intergroup exemestane study: large differences by country and geographical region (2004) (0)
Clinical relevance of p53 and k-ras mutations in non-small cell lung cancer (NSCLC) (2001) (0)
37. Multicenter, randomized study assessing the impact of amifostine on normal tissue radiation tolerance during head and neck cancer radiotherapy (2001) (0)
Abstract LB168: Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study (2022) (0)
39 P - Chemotherapy induced leukopenia as a predictor of response in small cell lung cancer (SCLC) (1996) (0)
Diagnosis and management of neck metastases from an unknown primary Diagnosi e trattamento delle metastasi laterocervicali da sede primitiva ignota (2005) (0)
Predictive Biomarkers and Personalized Medicine FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFRTKI Sensitivity across All LungCancer Histologies (2014) (0)
P3-228: Clinical utility of gene expression levels of ribonucleotide reductase subunit M1 (RRM1), tyrosyl-DNA phosphodiesterase (Tdp1), nuclear factor of activated T cells (NFAT) and BubR1 mRNA expression in completely resected chemonaive non-small-cell lung cancer (NSCLC) patients (p) (2007) (0)
70 Chemotherapy-induced leukopenia as a predictor of treatment outcome in small cell lung cancer (SCLC) (1997) (0)
Review of Polish and international guidelines on hormonal therapy in localized prostate cancer (2017) (0)
Time trends in overall survival (OS) gain in advanced non-small-cell lung cancer (NSCLC). (2013) (0)
2 Factors determining survival in SCLC patients (pts) with complete response to chemotherapy (1997) (0)
[P53 and P16 gene mutations in non-small cell lung cancer]. (2002) (0)
P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients (pts) with non-small cell lung cancer (NSCLC) (2000) (0)
5084 POSTER Receptor Conversion in Breast Cancer Brain Metastases (BM) (2011) (0)
[Pancoast tumor-like primary lung lymphoma]. (2007) (0)
In addition to:"Diagnosis and treatment of breast cancer. Recommendations of the Polish Union of Oncology" (Nowotwory J Oncol 2003; 53: 300-324) (2003) (0)
Concomitant renal cancer metastases to the pancreas and thyroid gland: case report and literature review (2015) (0)
Radiotherapy for Leptomeningeal Carcinomatosis in Breast Cancer Patients: A Narrative Review (2022) (0)
Prognostic significance of dose intensity and haematological toxicity in breast cancer patients administered with adjuvant CMF chemotherapy (2014) (0)
1632PARE BILATERAL BREAST CANCERS AND BREAST CANCERS COEXISTING WITH OVARIAN CANCER DIFFERENT FROM SOLITARY TUMORS? A PAIR-MATCHED IMMUNOHISTOCHEMICAL ANALYSIS AIMED AT INTRINSIC TUMOR PHENOTYPE. (2014) (0)
Assessment of quality of life (QOL) in phase III trials in advanced colorectal cancer (CRC). (2011) (0)
[Acute myeloid leukemia during Hodgkin's disease]. (1979) (0)
Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC). (2016) (0)
[The role of serum markers in diagnosis and treatment monitoring in patients with lung cancer]. (1995) (0)
Recommendations on the management of prostate cancer - a round table conference (2007) (0)
P-132 Prognostic relevance of tumor ploidy assessed by karyotyping innon-small cell lung cancer (NSCLC) (2005) (0)
[Bronchial carcinoid]. (1997) (0)
Abstract P6-11-04: Profound prevention of experimental brain metastases of breast cancer by temozolomide in a MGMT-dependent manner (2013) (0)
Complex EGFR mutations in non-small cell lung cancer: a distinct entity? (2022) (0)
298. Toxicity and survival following radical radiotherapy in bladder cancer patients – a single institution experience (2003) (0)
Breast cancer (BC) phenotypes in small invasive tumors (pT1a/b pN0). (2010) (0)
P2.01-81 Treatment of Superior Sulcus Tumor: A Twelve-Year Single-Center Experience (2018) (0)
Toxicity of molecular targeted agents in lung cancer. Do we need a new classification (2012) (0)
Cyclophosphamide, epirubicin and etoposide (CEE) in small cell lung cancer (SCLC) (1993) (0)
6506 ORAL A prognostic model based on BRCA1 mRNA expression: a new determinant of outcome in early non-small-cell lung cancer (NSCLC) (2007) (0)
Breast cancer molecular subtypes and the risk of second malignancies. (2009) (0)
High-dose chemotherapy in advanced breast cancer: the end of illusions? (2000) (0)
Arg72Pro P53 gene polymorphism: Clinical relevance and relation with P53 mutations in non-small cell lung cancer (NSCLC) patients (2004) (0)
Prognostic factors for long term survival in small cell lung cancer (SCLC) (1993) (0)
Indeed, Nuance Matters. (2019) (0)
Perspectives of non-small cell lung cancer treatment with angiogenesis inhibitors (2003) (0)
Analysis of XPD gene Lys751Gln polymorphism as predisposing factor for non-small cell lung cancer (NSCLC) development: P2-012 (2007) (0)
The role of chemotherapy dose-intensity in advanced breast cancer (2004) (0)
Clinical relevance of p53 protein expression in non-small cell lung cancer (NSCLC) patients (pts) (1998) (0)
Type and location of P53 suppressor gene mutations in 332 Polish non-small cell lung cancer (NSCLC) patients (2000) (0)
[Systemic treatment of patients with non small cell lung cancer: from nihilism to hope]. (2014) (0)
Nivolumab in patients with previously treated metastatic squamous non-small cell lung cancer (NSCLC): results of a European single-arm, phase II trial (CHECKMATE 171) including patients aged >= 70 years or with poor performance status. (2017) (0)
P2-12-05: Correlation between Quantitative HER2 Protein Expression and Risk of Brain Metastases in HER2−Positive Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy. (2011) (0)
Public perception of cancer care in Poland and Austria: A survey study. (2014) (0)
Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study (2023) (0)
Prognostic Significance of ESR 1 Amplification and ESR 1 PvuII , CYP 2 C 19 * 2 , UGT 2 B 15 * 2 Polymorphisms in Breast Cancer Patients (2013) (0)
[Adjuncts to surgery in cervical cancer]. (2005) (0)
Three secondary malignant neoplasms in a childhood cancer survivor positive for nibrin gene mutation – a case report and literature review (2019) (0)
Penile metastases from rectal carcinoma: case report and review of the literature (2006) (0)
Prediction of distant relapse risk in stage I-II non-small cell lung cancer (NSCLC) by gene expression profiling (2007) (0)
Hormone replacement therapy and breast cancer risk in view of recent studies (2000) (0)
The role of surgery in limited-disease small cell lung cancer (SCLC); a retrospective comparative study (2004) (0)
Molecular studies support the association between germ-line genetic variants in the vascular endothelial growth factor (VEGF) pathway and survival in non-small cell lung cancer (NSCLC) patients. (2011) (0)
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain (2012) (0)
Authors' Reply to Role of Primary Prevention in Lung Cancer Control in Poland. (2021) (0)
[Polychemotherapy using methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) in patients with advanced adenocarcinoma and large cell carcinoma of the lung]. (1986) (0)
Arg72Pro P53 gene polymorphism: Clinical relevance and relation with P53 mutations in non-small cell lung cancer (NSCLC) patients. (2004) (0)
The role of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer (2005) (0)
P-375 The influence of blood transfusion on survival in non-small cell lung cancer patients (2003) (0)
Role of hormonal treatment in the management of prostate cancer (2003) (0)
Surgical treatment of prostate cancer (2003) (0)
Late sequelae of radiotherapy in breast cancer (1998) (0)
Platelet RNA enables accurate detection of ovarian cancer: an intercontinental, biomarker identification study. (2022) (0)
[Telegammatherapy in patients with oral carcinoma]. (1984) (0)
Prognostic value of p53 gene mutations in NSCLC: negative impact in adenocarcinoma (1999) (0)
Immune response in breast cancer brain metastases (BM) and their microenvironment. (2015) (0)
The risk of distant metastases and prognosis prediction in early stage squamous cell lung cancer (SqCLC) by means of 3 microRNAs expression assessment (2011) (0)
Pattern of relapse and the risk of second malignancies in molecular subtypes of early breast cancer (BC). (2009) (0)
[Pleural mesothelioma--progress in diagnosis and treatment trials]. (1991) (0)
Cervix cancer brachytherapy: time for changes? (2006) (0)
Prognostic relevance of mdm2 protein expression in non-small cell lung cancer (2006) (0)
394 INVITED Is It Time to Review the Common Toxicity Criteria in the Era of New Targeted Drugs (2011) (0)
Abstract P5-04-01: Expression of epithelial-mesenchymal transition (EMT)-related markers in primary tumors and matched lymph node metastases in breast cancer patients (2012) (0)
Original paper Pulsed-dose-rate post-operative vaginal cuff brachytherapy for endometrial cancer: preliminary report (2015) (0)
P-482 Clinical relevance of molecular markers in non-small cell lung cancer (NSCLC) (2003) (0)
[Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)]. (2002) (0)
Gene copy numbers and expression of ErbB-1 and ErbB-2 in breast cancer (2006) (0)
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer (2018) (0)
Modern management of symptoms and quality of life. (2003) (0)
ED10.03 New Developments in Radiotherapy of Stage III NSCLC (2017) (0)
Dual HER 2 Blockade Chair : (2017) (0)
The neuronal cell adhesion molecule L1CAM as a therapeutic targe in breast cancer. (2011) (0)
48. MicroRNA prognostic signature for distant relapse in early stage colon cancer (2016) (0)
[Lymphatic metastases of malignant melanoma of unknown primary site]. (1980) (0)
Adjuvant treatment of patients with rectal cancer (1997) (0)
European academics fight for the health of clinical trials (2014) (0)
484 Germline Variants in Angiogenesis Genes as Markers of Progression-free Survival in Stage I-III Non-small Cell Lung Cancer Patients (2012) (0)
Chairperson's Introduction (2007) (0)
Genomic characterization of brain metastases (BM) in high-grade serous ovarian cancer (HGSOC). (2019) (0)
P-153 The prognostic value of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients (2003) (0)
Gene expression signatures in non-small cell lung cancer (NSCLC) according to cigarette smoking history (2008) (0)
P-029 MDM2 gene amplification and expression in NSCLC cells: Biological and clinical implications (2005) (0)
Outcome and prognostic factors in primary uterine leiomyosarcoma: a rare cancer network study (2001) (0)
173. Does the correlation between chemotherapy-induced leukopenia with response in locally advanced breast cancer exist? (2003) (0)
Factors determining late complications following postoperative radiotherapy in endometrial carcinoma (1997) (0)
Prognostic relevance of mdm 2 protein expression in non-small cell lung cancer (2007) (0)
[Paraneoplastic syndromes in lung cancer]. (1994) (0)
Factors determining the efficacy of tamoxifen treatment in breast cancer patients (2010) (0)
Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review (2023) (0)
Prognostic significance of aneuploidy in non-small cell lung cancer (NSCLC) patients (pts). (2004) (0)
Breast cancer – where are we standing in 2011? (2011) (0)
[Systemic treatment of non-small cell lung cancer--recommendations based on the results of reliable clinical trials]. (2007) (0)
Albumin as a probe for clathrin-independent endocytosis and transcytosis into experimental brain metastases of breast cancer. (2022) (0)
The role of screening for prostate cancer (2003) (0)
[Comparison of 2 regimens of chemotherapy of small cell carcinoma of the lung: modified Hansen method and the ACOM method]. (1988) (0)
[Evaluation of the second line of treatment of patients with small cell carcinoma of the lung]. (1989) (0)
Abnormalities of erbB oncogene family in breast cancer (2004) (0)
15. Combined chemotherapy and radiation in locally advanced inoperable NSCLC (2003) (0)
296. Spinal cord ependymoma: A Retrospective study of 12 patients (2003) (0)
Consensus on medical treatment of metastatic breast cancer: a central european initiative (2006) (0)
Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping Review (2021) (0)
Late sequelae of breast cancer treatment, are they preventable? Radiotherapy (2004) (0)
Systemic therapy for advanced anal canal carcinoma. Case report and a review of the literature (2013) (0)
150. Multicenter, randomized study assessing the impact of amifostine on normal tissue tolerance during radiotherapy for head and neck cancer (2003) (0)
Locoregional control significantly reduces the risk of subsequent distant metastases in patients with locally advanced breast cancer managed with radiotherapy as the primary locoregional treatment (2007) (0)
MTE 25.01 Smoking after Diagnosis of Cancer (2017) (0)
Molecular aspects of brain metastases in breast cancer. (2023) (0)
Perspectives for Cancer Care and Research in Central and Eastern Europe (2022) (0)
Combining chemotherapy with radiation in breast cancer (2008) (0)
The role of chemotherapy in soft tissue sarcomas (2003) (0)
OA01.04 First-Line Nivolumab + Ipilimumab + Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update (2023) (0)
Platelet-Based Liquid Biopsies through the Lens of Machine Learning (2023) (0)
Recurrent endometrial cancer (EC) after surgery alone: Results of salvage radiotherapy (RT) (1999) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jacek Jassem?

Jacek Jassem is affiliated with the following schools:

Jacek Jassem's Academic­Influence.com Rankings

Why Is Jacek Jassem Influential?

Jacek Jassem's Published Works

Published Works

What Schools Are Affiliated With Jacek Jassem?

Jacek Jassem's AcademicInfluence.com Rankings